EHA 2022

EHA 2022
June 09-12, 2022

The European Hematology Association (EHA) 2022.

Explore more information for Gilead Oncology therapies
Results (4)

A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

Impact of magrolimab treatment in combination with azacitidine on red blood cells in higher-risk myelodysplastic syndrome (HR-MDS) patients